Bacteria: Gram-positive

Staphylococcus aureus

including methicillin-resistant S. aureus (MRSA)

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A Gram-positive coccus in clusters carried on the skin and in the nose of many people, and a major cause of skin, soft-tissue and invasive infection.

Infections

Boils, abscesses, cellulitis and wound infection; pneumonia; bloodstream infection and endocarditis; bone and joint infection; device infection. Uncommon as a primary urinary pathogen.

Signs and symptoms

Red, warm, painful skin with pus; fever; in urine, may indicate bloodstream infection.

Antibiotic and antimicrobial resistance

mecA (mecA) confers methicillin resistance (MRSA). Some strains carry the PVL toxin (PVL).

Treatment considerations

Drainage of abscesses; MSSA: anti-staphylococcal beta-lactams (for example cefazolin). MRSA: vancomycin, daptomycin, linezolid, or oral agents such as doxycycline or trimethoprim-sulfamethoxazole for selected skin infection. S. aureus bacteremia warrants specialist management.

Infection control and public health

MRSA: contact precautions per facility policy; hand hygiene.

Clusters of round MRSA cells, colorized scanning electron micrograph
Methicillin-resistant Staphylococcus aureus (MRSA), scanning electron micrograph (colorized). NIAID/NIH; public domain. Image source
Gram-positive cocci in clusters, schematic
Gram-positive cocci in clusters. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Staphylococcus aureus.
  2. CDC. MRSA.
  3. IDSA. Skin and Soft Tissue Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.